恒瑞医药：注射用甲苯磺酸瑞马唑仑的药品上市许可申请获受理

Core Viewpoint - Heng Rui Medicine (600276.SH) has received the acceptance notice from the National Medical Products Administration for its drug application of injectable tofenamic acid remimazolam, indicating progress in its drug development pipeline [1] Group 1: Drug Information - Tofenic acid remimazolam is a benzodiazepine drug and a short-acting GABAa receptor agonist, which produces sedative and anesthetic effects by inhibiting neuronal activity [1] - The advantages of tofenamic acid remimazolam include rapid onset, short recovery time, and minimal impact on respiratory and cardiovascular systems [1] Group 2: Market Context - The drug was developed by PAION AG and has been approved in Japan in January 2020, in the United States in October 2020, and in China in July 2020 [1] - The global sales of remimazolam are projected to reach approximately $59.22 million in 2024 [1] Group 3: R&D Investment - The cumulative research and development investment for injectable tofenamic acid remimazolam has reached approximately 184 million yuan [1]